Anti-VEGF in diabetic retinopathy and diabetic macular edema

References

• IDF Diabetes Atlas. Brussels, Belgium: International Diabetes Federation; 2013. Available from: http://www.idf.org/idf-diabetes-atlas-seventh-edition
   Google Scholar
• Usuelli V, La Rocca E. Novel therapeutic approaches for diabetic nephropathy and retinopathy. Pharmacological Res. 2015;98:39–44. DOI:10.1016/j.phrs.2014.10.003.
   PubMed Web of Science ®Google Scholar
• Yau JW, Rogers SL, Kawasaki R, et al. Meta-analysis for eye disease (META-EYE) study group global prevalence and risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556–564.
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BEK, Moss SE, et al. The wisconsin epidemiologic study of diabetic retinopathy: XV: the long-term incidence of macular edema. Ophthalmology. 1995;102:7–16.
   PubMed Web of Science ®Google Scholar
• Zhang X, Saaddine JB, Chou CF, et al. Prevalence of diabetic retinopathy in the United States. Jama. 2010;304(6):649–656.
   PubMed Web of Science ®Google Scholar
• Aiello LM. Perspectives on diabetic retinopathy. Am J Ophthalmol. 2003;136:122.
   PubMed Web of Science ®Google Scholar
• http://www.uptodate.com/contents/diabetic-retinopathy-classification-and-clinical-features?source=search_result&search=diabetic+retinopathy&selectedTitle=1~133#H4
   Google Scholar
• Early treatment diabetic retinopathy study (ETDRS) research group: photocoagulation for diabetic macular edema. ETDRS report. Arch Ophthalmol. 1985;103:1796–1806. Available from: https://www.ncbi.nlm.nih.gov/pubmed/2866759?dopt=Abstract
   PubMed Web of Science ®Google Scholar
• Lightman S, Towler HM. Diabetic retinopathy. Clin Cornerstone. 2003;5:12–21.
   PubMedGoogle Scholar
• Cunha-Vaz JG. The blood–ocular barriers. Surv Ophthalmol. 1979;23:279–296.
   PubMed Web of Science ®Google Scholar
• Cunha-Vaz JG, Maurice DM. Fluorescein dynamics in the eye. Doc Ophthalmol. 1969;26:61–72.
   PubMed Web of Science ®Google Scholar
• Cunha-Vaz JG, Shakib M, Ashton N. Studies on the permeability of the blood-ocular barrier. I. On the existence, development and site of a blood–retinal barrier. Br J Ophthalmol. 1966;50:411–453.
   Web of Science ®Google Scholar
• Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615–1625.
   PubMed Web of Science ®Google Scholar
• Van Dieren S, Beulens JWJ, Van Der Schouw YT, et al. The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil. 2010;17(1):S3–S8. DOI:10.1097/01.hjr.0000368191.86614.5a.
   Google Scholar
• Hendrick AM, Gibson MV, Kulshreshtha A. Diabetic retinopathy. Prim Care. 2015;42(3):451–464. DOI:10.1016/j.pop.2015.05.005.
   PubMed Web of Science ®Google Scholar
• Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813–820. DOI:10.1038/414813a.
   PubMed Web of Science ®Google Scholar
• Durham JT, Herman IM. Microvascular modifications in diabetic retinopathy. Curr Diab Rep. 2011;11(4):253–264. DOI:10.1007/s11892-011-0204-0.
   PubMed Web of Science ®Google Scholar
• Semeraro F, Cancarini A, Dell’omo R, et al. Diabetic retinopathy: vascular and inflammatory disease. J Diabetes Res. 2015;2015:16. DOI:10.1155/2015/582060.58206.
   Google Scholar
• Rangasamy S, McGuire PG, Franco Nitta C, et al. Chemokine mediated monocyte trafficking into the retina: role of inflammation in alteration of the blood-retinal barrier diabetic retinopathy. PLoS One. 2014;9:e108508.
   PubMed Web of Science ®Google Scholar
• Tah V, Orlans HO, Hyer J, et al. Anti-VEGF therapy and the retina: an update. J Ophthalmology. 2015;2015. 627674.
   PubMed Web of Science ®Google Scholar
• Arroyo JG. Towards a rational approach to combination therapy for neovascular age related macular degeneration. Br J Ophthalmol. 2007;91(2):130–131. DOI:10.1136/bjo.2006.106534.
   PubMed Web of Science ®Google Scholar
• Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480–1487. DOI:10.1056/nejm199412013312203.
   PubMed Web of Science ®Google Scholar
• Funatsu H, Yamashita H, Ikeda T, et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology. 2003;110:1690–1696.
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25:581–611.
   PubMed Web of Science ®Google Scholar
• Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol. 2006;39:469–478.
   PubMedGoogle Scholar
• R Simo, JM Sundstrom, DA Antonetti. ocular anti-VEGF therapy for diabetic retinopathy: the role of VEGF in the pathogenesis of diabetic retinopathy. Diabetes Care. 2014;37:893–899. DOI:10.2337/dc13-2002
   PubMed Web of Science ®Google Scholar
• Olsson AK, Dimberg A, Kreuger J, et al. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006;7:359–371.
   PubMed Web of Science ®Google Scholar
• Hirsch IB, Brownlee M. Beyond hemoglobin A1c–need for additional markers of risk for diabetic microvascular complications. Jama. 2010;303:2291–2292.
   PubMed Web of Science ®Google Scholar
• Nathan DM, Zinman B, Cleary PA. Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration: the Diabetes Control and Complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med. 2009;169:1307–1316.
   PubMed Web of Science ®Google Scholar
• Romero-Aroca P, Reyes-Torres J, Baget-Bernaldiz M, et al. Laser treatment for diabetic macular edema in the 21st century. Curr Diabetes Rev. 2014 Mar;10(2):100–112.
   PubMedGoogle Scholar
• Stefánsson E. The mechanism of retinal photocoagulation – how does the laser work? Eur Ophthalmic Rev. 2009;2(1):76–79.
   Google Scholar
• Titchenell PM, Antonetti DA. Using the past to inform the future: anti-VEGF therapy as a road map to develop novel therapies for diabetic retinopathy. Diabetes. 2013;62:1808–181.
   PubMed Web of Science ®Google Scholar
• DRCR.net. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008;115:1447–1449.
   PubMed Web of Science ®Google Scholar
• Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema; diabeticretinopathy clinical research network. Ophthalmology. 2011 Apr;118(4):609–614. DOI:10.1016/j.ophtha.2010.12.033
   PubMed Web of Science ®Google Scholar
• Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): A 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33:2399–2405.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Brown DM, Marcus DM, et al. RISE and RIDE research group: ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789–801.
   PubMed Web of Science ®Google Scholar
• Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol. 2012;130:872–979.
   Google Scholar
• Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121:2247–2254.
   PubMed Web of Science ®Google Scholar
• Brown DM, Schmidt-Erfurth U, Dv D, et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology. 2015 Oct;122(10):2044–2052. Epub 2015 Jul 18. DOI:10.1016/j.ophtha.2015.06.017
   PubMed Web of Science ®Google Scholar
• Elman MJ, Aiello LP, Beck RW, et al., DRCR.net. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064–1077.
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR, Ayala AR, et al. Diabetic retinopathy clinical research network. aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016 Jun;123(6):1351–1359. Epub 2016 Feb 27. DOI:10.1016/j.ophtha.2016.02.022
   PubMed Web of Science ®Google Scholar
• Au A, Singh RP. A multimodal approach to diabetic macular edema. J Diabetes Complications. 2016 May 01;30(3):545–553.
   PubMed Web of Science ®Google Scholar
• Chang-Lin JE, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52:80–86.
   PubMed Web of Science ®Google Scholar
• Escobar-Barranco JJ, Pina-Marin B, Fernandez-Bonet M. Dexamethasone implants in patients with naïve or refractory diffuse diabetic macular edema. Ophthalmologica. 2014. DOI:10.1159/000371770.
   Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized trial. Jama. 2015;314(20): 2137–2146. DOI:10.1001/jama.2015.15217
   PubMed Web of Science ®Google Scholar
• Smith JM, Steel DH. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Cochrane Database Syst Rev. 2011;5:CD008214.
   Google Scholar
• Avery RL, Bakri SJ, Blumenkranz MS, et al. Intravitreal injection technique and monitoring: updated guidelines of an expert panel. Retina. 2014;34(12):S1–S18.
   PubMedGoogle Scholar
• Ophthalmic Mutual Insurance Company. Consent Forms. Avastin Intravitreal Injection Consent. Available from: www.omic.com/avastin-intravitreal-injection-consent/. cited 2014 Sep 9.
   Google Scholar
• The Royal College of Ophthalmologists. Guidelines for intravitreal injections procedure 2009. Available from: www.rcophth.ac.uk/page.asp?section=451. cited 2014 Sep 4.
   Google Scholar
• American Academy of Ophthalmology. Age-related macular degeneration, preferred practice pattern. San Francisco: American Academy of Ophthalmology; 2015. [cited 2015 Sep 15]. Available from www.aao.org/ppp
   Google Scholar
• Fung AE, Rosenfeld PJ, Reichel E. The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90:1344–1349.
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Flynn HW Jr. Endophthalmitis after intravitreal injection: prevention and management. Retina. 2011;31:633–635.
   PubMed Web of Science ®Google Scholar
• Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol. 2011 Mar-Apr; 56(2):95–113. DOI:10.1016/j.survophthal.2010.08.006
   PubMed Web of Science ®Google Scholar
• Jager RD, Aiello LP, Patel SC. Cunningham ET: Risks of intravitreous injection: a comprehensive review. Retina. 2004;24:676–698.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Lucentis (ranibizumab injection). BLA 25156. Available from:www.accessdata.fda.gov/drugsatfda_docs/label/2006/125156lbl.pdf. cited 2014 Dec 11
   Google Scholar
• Meyer CH, Michels S, Rodrigues EB, et al. Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections. Acta Ophthalmol. 2011;89:70–75.
   PubMed Web of Science ®Google Scholar
• McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Retina. 2011;31:654–661. [PubMed].
   PubMed Web of Science ®Google Scholar
• Scott IU, Flynn HW Jr. Reducing the risk of endophthalmitis following intravitreal injections. Retina. 2007;27:10–12.
   PubMed Web of Science ®Google Scholar
• Ghasemi Falavarjani. K, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond). 2013 Jul;27(7):787–794.
   PubMed Web of Science ®Google Scholar
• Mezad-Koursh D, Goldstein M, Heilwail G, et al. Clinical characteristics of endophthalmitis after an injection of intravitreal antivascular endothelial growth factor. Retina. 2010 Jul-Aug;30(7):1051–1057.
   PubMed Web of Science ®Google Scholar
• Irigoyen C, Ziahosseini K, Morphis G, et al. Endophthalmitis following intravitreal injections. Graefes Arch Clin Exp Ophthalmol. 2012 Apr;250(4):499–505.
   PubMed Web of Science ®Google Scholar
• Tabandeh HMD, Boscia MS, Francesco MD, et al. Endophthalmitis associated with intravitreal injections: office-based setting and operating room setting. Retina. 2014 Jan;34(1):18–23.
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Pulido JS, McCannel CA, et al. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. J Eye (Lond). 2009 Jan;23(1):181–185.
   PubMed Web of Science ®Google Scholar
• Gismondi M, Salati C, Salvetat ML, et al. Short-term effect of intravitreal injection of ranibizumab (lucentis) on intraocular pressure. J Glaucoma. 2009 Dec;18(9):658–661.
   PubMed Web of Science ®Google Scholar
• Kahook MY, Kimura AE, Wong LJ, et al. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging. 2009;40:293–295. PubMed.
   PubMed Web of Science ®Google Scholar
• Hoang QV, Mendonca LS, Della Torre KE, et al. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology. 2012;119:321–326. PubMed.
   PubMed Web of Science ®Google Scholar
• Good TJ, Kimura AE, Mandava N, et al. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol. 2011;95:1111–1114. PubMed.
   PubMed Web of Science ®Google Scholar
• Ladas ID, Karagiannis DA, Rouvas AA, et al. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. Retina. 2009;29(3):313–318.
   PubMed Web of Science ®Google Scholar
• Thulliez M, Angoulvant D, Le Lez ML, et al. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis. JAMA Ophthalmol. 2014 Nov;132(11):1317–1326. DOI:10.1001/jamaophthalmol.2014.2333
   PubMed Web of Science ®Google Scholar
• Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005;46(2):726–733.
   PubMed Web of Science ®Google Scholar
• Zehetner C, Kirchmair R, Huber S, et al. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol. 2013;97(4):454–459.
   PubMed Web of Science ®Google Scholar
• Avery RL, Gordon GM. Systemic safety of prolonged monthly anti–vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis. JAMA Ophthalmol. 2016;134(1):21–29. DOI:10.1001/jamaophthalmol.2015.4070.
   PubMed Web of Science ®Google Scholar
• Das A, McGuire P, Rangasamy S. Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology. 2015 Jul 01; 122(7):1375–1394.
   PubMed Web of Science ®Google Scholar